Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [68Ga]PSMA-PET-guided metastasis-directed therapy.
Marco M E VogelStephanie G C KroezeChristoph HenkenberensNina-Sophie Schmidt-HegemannSimon KirsteJessica BeckerIrene Andrea BurgerThorsten DerlinPeter BartensteinMichael MixChristian Peter la FougèreMatthias EiberHans ChristiansenClaus BelkaAnca-Ligia GrosuArndt-Christian MüllerMatthias GuckenbergerStephanie Elisabeth CombsPublished in: European journal of nuclear medicine and molecular imaging (2020)
We developed and internally validated a risk classification for bRFS after PSMA-PET-guided MDT. Patients with PSA < 0.8 ng/mL and local relapse only (LR and/or pelvic LNs) had the most promising bRFS. PSA ≥ 0.8 ng/mL and local relapse only (LR and/or pelvic LNs) indicated intermediate risk for failure. Patients with BM were at higher risk regardless of the PSA. However, those patients still show satisfactory bRFS. In patients with VM, bRFS is heavily decreased. MDT in such cases should be discussed individually.